Floatz logo

Orvepitant

Depressive Disorder

GlaxoSmithKlineSmall moleculePhase 2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

91 Active assets in the Depressive Disorder cohort.

Asset / SponsorPhaseRating
Opc-34712
Dr. Albert Kar-Kin Chung
Phase 4A
S-Ketamine
Janssen Korea, Ltd., Korea
Phase 4A
Paroxetine
GlaxoSmithKline
Phase 4BBB
S-Ketamine
Chinese PLA General Hospital
Phase 4BBB
Saredutant
Sanofi
Phase 3BBB

View all 50 →

Same molecule, other indications

Orvepitant is also rated in:

CoughDormant
CC
Indicative ·
44 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CC
Indicative ·
44 / 100
View asset →
major depressive disorderDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →